Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy

AIDS

Volumn 17, Issue 6, 2003, Pages 924-927

  Paolucci, Stefania ^a   Baldanti, Fausto ^a   Tinelli, Marco ^b   Maga, Giovanni ^c   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Divisione di Malattie Infettive   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CASE REPORT; GENE INSERTION; GENE MAPPING; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; MUTANT; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037625913     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304110-00022     Document Type: Article

References (15)

1. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999, 179:1375-1381.
2. De Gruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000, 5:41-48.
3. Loveday C. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001, 26 (Suppl. 1):10-24.
4. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999, 43:1961-1967.
5. Deeks SG. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001, 26 (Suppl. 1):25-33.
6. Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L, et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001, 65:207-217.
7. Shafer RW, Dupnik K, Winters MA, Eshleman SH. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. In: Human retroviruses and AIDS, theoretical biology and biophysics. Los Alamos, NM: Los Alamos National Laboratories, 2001; pp. 1-51.
8. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucl Acids Res 2001, 29:296-299.
9. Higuchi R. Recombinant PCR. In: PCR protocols. A guide to method and applications. White TJ (editor). San Diego, CA: Academic Press Inc.; 1990; pp. 176-183.
10. Boucher C, Keulen W, van Bommel, T, Nijhuis M, de Jong D, de Jong MD, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996, 40:2404-2409.
11. Cattaneo E, Zavattoni M, Baldanti F, Sarasini A, Caselli D, Maccabruni A, et al. Diagnostic value of viral culture, polymerase chain reaction and Western blot for HIV-1 infection in 218 infants born to HIV-infected mothers and examined at different ages. New Microbiologica 1999, 22:281-291.
12. The AIDS Clinical Trials Group Virology Technical Advisory Committee and the Division of AIDS, National Institutes of Allergy and Infectious Diseases. HIV drug susceptibility assay. ACTG Virology Manual for HIV laboratories. Bethesda, MD: Division of AIDS, National Institutes of Allergy and Infectious Diseases; 1994. RES 1-12.
13. Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci 2000, 57:1408-1422.
14. Huang H, Chopra R, Vedine GL, Harrison S. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669-1675.
15. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viremia in HIV-1-infected patients with antantiretroviral combination therapy. AIDS 2002, 16:1039-1044.